Video_1_Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension.mp4
Pulmonary hypertension secondary to bronchopulmonary dysplasia (BPD-PH) represents a major complication of BPD in extremely preterm infants for which there are currently no safe and effective interventions. The abundance of interleukin-1 (IL-1) is strongly correlated with the severity and long-term outcome of BPD infants and we have previously shown that IL-1 receptor antagonist (IL-1Ra) protects against murine BPD; therefore, we hypothesized that IL-1Ra may also be effective against BPD-PH. We employed daily injections of IL-1Ra in a murine model in which BPD/BPD-PH was induced by antenatal LPS and postnatal hyperoxia of 65% O2. Pups reared in hyperoxia for 28 days exhibited a BPD-PH-like disease accompanied by significant changes in pulmonary vascular morphology: micro-CT revealed an 84% reduction in small vessels (4–5 μm diameter) compared to room air controls; this change was prevented by IL-1Ra. Pulmonary vascular resistance, assessed at day 28 of life by echocardiography using the inversely-related surrogate marker time-to-peak-velocity/right ventricular ejection time (TPV/RVET), increased in hyperoxic mice (0.27 compared to 0.32 in air controls), and fell significantly with daily IL-1Ra treatment (0.31). Importantly, in vivo cine-angiography revealed that this protection afforded by IL-1Ra treatment for 28 days is maintained at day 60 of life. Despite an increased abundance of mediators of pulmonary angiogenesis in day 5 lung lysates, namely vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1), no difference was detected in ex vivo pulmonary vascular reactivity between air and hyperoxia mice as measured in precision cut lung slices, or by immunohistochemistry in alpha-smooth muscle actin (α-SMA) and endothelin receptor type-A (ETA) at day 28. Further, on day 28 of life we observed cardiac fibrosis by Sirius Red staining, which was accompanied by an increase in mRNA expression of galectin-3 and CCL2 (chemokine (C-C motif) ligand 2) in whole hearts of hyperoxic pups, which improved with IL-1Ra. In summary, our findings suggest that daily administration of the anti-inflammatory IL-1Ra prevents the increase in pulmonary vascular resistance and the pulmonary dysangiogenesis of murine BPD-PH, thus pointing to IL-1Ra as a promising candidate for the treatment of both BPD and BPD-PH.
History
References
- https://doi.org//10.1016/j.siny.2009.08.007
- https://doi.org//10.1542/peds.2009-2959
- https://doi.org//10.1016/j.ajog.2006.09.014
- https://doi.org//10.1016/j.jpeds.2015.07.067
- https://doi.org//10.1038/sj.jp.7211476
- https://doi.org//10.1111/j.1651-2227.2004.tb02926.x
- https://doi.org//10.1136/thx.2008.103739
- https://doi.org//10.1542/peds.2011-1827
- https://doi.org//10.1542/peds.2007-0971
- https://doi.org//10.1053/j.semperi.2018.09.002
- https://doi.org//10.3389/fmed.2016.00021
- https://doi.org//10.1146/annurev.physiol.67.040403.102229
- https://doi.org//10.1016/j.prrv.2010.05.001
- https://doi.org//10.3345/kjp.2010.53.6.688
- https://doi.org//10.1053/j.semperi.2013.01.009
- https://doi.org//10.1038/jp.2016.10
- https://doi.org//10.1016/j.jacc.2009.04.006
- https://doi.org//10.1378/chest.11-0793
- https://doi.org//10.1073/pnas.1306859110
- https://doi.org//10.1016/S0022-3476(98)70392-0
- https://doi.org//10.1152/ajplung.00185.2005
- https://doi.org//10.1542/peds.2005-0620I
- https://doi.org//10.1513/AnnalsATS.201312-424LD
- https://doi.org//10.1038/nrd3800
- https://doi.org//10.1165/rcmb.2016-0031OC
- https://doi.org//10.1111/jcmm.13044
- https://doi.org//10.3109/01902149109064406
- https://doi.org//10.1203/PDR.0b013e31820bcb2a
- https://doi.org//10.1016/S0008-6363(99)00274-6
- https://doi.org//10.1186/1472-6793-9-11
- https://doi.org//10.1371/annotation/1baecd19-92b6-4683-b7d7-39c13a3f2e15
- https://doi.org//10.1038/nmeth.2019
- https://doi.org//10.1165/rcmb.2013-0247OC
- https://doi.org//10.1161/HYPERTENSIONAHA.109.131110
- https://doi.org//10.1016/j.bbalip.2003.11.007
- https://doi.org//10.1093/nar/29.9.e45
- https://doi.org//10.1152/japplphysiol.00205.2011
- https://doi.org//10.1186/s12859-017-1934-z
- https://doi.org//10.1542/peds.2007-1583
- https://doi.org//10.1007/s12471-011-0226-x
- https://doi.org//10.1152/japplphysiol.00987.2016
- https://doi.org//10.1161/HYPERTENSIONAHA.118.11874
- https://doi.org//10.1016/j.lfs.2015.10.025
- https://doi.org//10.1136/thx.2007.079608
- https://doi.org//10.1152/ajplung.2000.279.3.L600
- https://doi.org//10.1164/ajrccm.151.5.7735624
- https://doi.org//10.1161/CIRCULATIONAHA.109.933762
- https://doi.org//10.1183/09031936.00151313
- https://doi.org//10.1183/13993003.01448-2015
- https://doi.org//10.1177/2045893217729096
- https://doi.org//10.1111/j.1749-6632.1994.tb39794.x
- https://doi.org//10.1002/ppul.20851
- https://doi.org//10.1164/rccm.201809-1631LE
- https://doi.org//10.1165/ajrcmb.16.5.9160838
- https://doi.org//10.1159/000014168
- https://doi.org//10.1164/ajrccm.159.5.9806073
- https://doi.org//10.1152/ajplung.00325.2001
- https://doi.org//10.1165/rcmb.2007-0024OC
- https://doi.org//10.1016/j.ydbio.2003.09.004
- https://doi.org//10.1016/0014-5793(95)00956-A
- https://doi.org//10.1016/j.bbrc.2004.12.032
- https://doi.org//10.1074/jbc.C800207200
- https://doi.org//10.1542/peds.2008-0526
- https://doi.org//10.1080/jmf.14.3.205.211
- https://doi.org//10.1097/01.PCC.0000185483.09667.CB
- https://doi.org//10.1136/adc.2007.121327
- https://doi.org//10.1016/j.febslet.2008.02.021
- https://doi.org//10.1203/00006450-200009000-00005
- https://doi.org//10.1203/01.pdr.0000233056.37254.0b
- https://doi.org//10.1164/ajrccm/148.2.519
- https://doi.org//10.1152/jappl.1994.77.3.1051
- https://doi.org//10.1016/0006-291X(90)91948-R
- https://doi.org//10.1152/japplphysiol.00820.2002
- https://doi.org//10.1371/journal.pone.0173044
- https://doi.org//10.1111/1440-1681.12909
- https://doi.org//10.15190/d.2015.33
- https://doi.org//10.1093/eurjhf/hfp097
- https://doi.org//10.2741/s33
- https://doi.org//10.1007/s11897-017-0343-y
- https://doi.org//10.1161/01.HYP.25.3.421
- https://doi.org//10.1155/2012/962347
- https://doi.org//10.1016/j.jri.2017.09.013
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity